Dépôts auprès de la SEC

October 13, 2025

Form: 6-K
On October 13, 2025, Biophytis S.A. issued a press release announcing that Biophytis and a consortium of investors including RONGHUI RENHE Life Technology join forces to finance and launch first ever Phase-3 trial in sarcopenia.
Ouvrir le document

September 15, 2025

Form: 6-K
On September 15, 2025, Biophytis S.A. issued a press release announcing that the company secures public funding in Brazil for obesity phase 2 prial and signs agreements with leading local clinical partners with BIO101 in Europe and Asia.
Ouvrir le document

September 11, 2025

Form: 6-K
On September 11, 2025, Biophytis S.A. issued a press release unveiling Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia.
Ouvrir le document

September 1, 2025

Form: 6-K
On September 1, 2025, Biophytis S.A. issued a press release unveiling Phase-2 Obesity Trial Strategy with BIO101 in Europe and Brazil.
Ouvrir le document

August 28, 2025

Form: 6-K
On August 28, 2025, Biophytis S.A. issued a press release announcing that it has received EMA and Belgian regulatory approval to initiate Phase 3 Sarcopenia clinical trial.
Ouvrir le document

August 5, 2025

Form: 6-K
On August 5th, 2025, Biophytis S.A. issued a press release announcing the successful completion of a financial line of bonds debt.
Ouvrir le document

July 25, 2025

Form: 6-K
On July 25, 2025, Biophytis S.A. issued its 2024 Financial Report.
Ouvrir le document

July 11, 2025

Form: 6-K
On July 11, 2025, Biophytis S.A. issued a press release announcing the publication of its 2024 financial results.
Ouvrir le document

July 8, 2025

Form: 6-K On July 8, 2025, Biophytis S.A. issued a press release announcing its participation in the 7th edition of the World Aging & Rejuvenation Conference (ARC
2025).
Ouvrir le document

July 3, 2025

Form: 6-K
On July 3, 2025, Biophytis S.A. issued a press release announcing its successful participation at the BIO International Convention 2025.
Ouvrir le document

June 30, 2025

Form: 6-K
On June 30, 2025, Biophytis S.A. issued a press release announcing that it is not in a position to publish its 2024 annual accounts on the previously scheduled date.
Ouvrir le document

June 24, 2025

Form: 6-K
On June 19, 2025, Biophytis S.A. issued a press release announcing the temporary suspension of the trading of its shares.
Ouvrir le document

June 4, 2025

Form: 6-K
On June 4, 2025, Biophytis S.A. issued a press release announcing its participation in the BIO International Convention from June 16 to 19.
Ouvrir le document

June 2, 2025

Form: 6-K
On June 2, 2025, Biophytis S.A. issued a press release announcing that, due to exceptional circumstances related to technical complications in the audit process, the publication of its 2024 annual financial statements has been postponed.
Ouvrir le document

May 15, 2025

Form: 6-K
On May 15, 2025, Biophytis S.A. issued a press release announcing its active participation at the 32nd European Congress on Obesity (ECO 2025).
Ouvrir le document

April 29, 2025

Form: 20-F
Notification of Late Filing (Form NT 20-F) for Biophytis SA due to management resources focused on refinancing (€2.5M gross, €2.2M net), delaying the annual report (Form 20-F) filing for fiscal year ended December 31, 2024, expected within the allowed 15-day extension.
Ouvrir le document

April 25, 2025

Form: 6-K
On April 25, 2025, Biophytis S.A. issued a press release announcing the postponement of the publication of the annual financial statements.
Ouvrir le document

April 22, 2025

Form: 6-K
On April 22, 2025, Biophytis S.A. issued a press release announcing that the company targets mobility restoration in patients with obesity.
Ouvrir le document

April 8, 2025

Form: 6-K
On April 8, 2025, Biophytis S.A. issued a press release confirming the Launch of the phase 2 OBA Clinical Trial in Obesity.
Ouvrir le document

March 28, 2025

Form: 6-K
On March 28, 2025, Biophytis S.A. issued a press release announcing the settlement and delivery of its €2.6 million private placement.
Ouvrir le document

March 26, 2025

Form: 6-K
On March 26, 2025, Biophytis S.A. issued a press release announcing the successful completion of a €2.6 million private placement.
Ouvrir le document

January 21, 2025

Form: 6-K
On January 21, 2025, Biophytis S.A. issued a press release announcing the signing of a co-development agreement with AskHelpU, the largest association in China for those affected by amyotrophic lateral sclerosis (ALS).
Ouvrir le document

January 14, 2025

Form: 6-K
On January 14, 2025, Biophytis S.A. issued a press release announcing that the company enters exclusive negotiations with a Chinese pharmaceutical company to license BIO101.
Ouvrir le document

January 6, 2025

Form: 6-K
On January 6, 2025, Biophytis S.A. (the “Company”) issued a press release announcing the temporary suspension of the listing of its ordinary shares and share warrants on the Euronext Growth market.
Ouvrir le document

September 30, 2024

Form: 6-K
On September 30, 2024, Biophytis S.A. (the “Company”) issued its Interim Financial Report for the first half of fiscal year 2024.
Ouvrir le document

July 22, 2024

Form: 6-K
On July 22, 2024, Biophytis S.A. issued a press release announcing the deployment of its partnership strategy in Asia.
Ouvrir le document

July 11, 2024

Form: 6-K
On July 11, 2024, Biophytis S.A. issued a press release announcing that Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity.
Ouvrir le document

July 1, 2024

Form: 6-K
On July 1, 2024, Biophytis S.A. issued a press release announcing the presentation of its Phase 2-3 COVA study results in severe forms of COVID-19 at the WCID in Paris.
Ouvrir le document

June 20, 2024

Form: 6-K
On June 20, 2024, Biophytis S.A. issued a press release announcing that Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up €108 Million.
Ouvrir le document

June 20, 2024

Form: 6-K
 On June 19, 2024, Biophytis S.A. issued a press release announcing that Biophytis extends its contract with Atlas to secure financing for its business activities. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.
Ouvrir le document

June 14, 2024

Form: 6-K
On June 12, 2024, Biophytis S.A. issued a press release announcing the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens.
Ouvrir le document

June 11, 2024

Form: 6-K
On June 10, 2024, Biophytis S.A. issued a press release announcing filing of IND application with the US FDA for its phase 2 study in obesity.
Ouvrir le document

June 7, 2024

Form: 6-K
On June 7, 2024, Biophytis S.A. issued a press release announcing that it will hold a Combined General Meeting (CGM) on June 24, 2024.
Ouvrir le document

May 14, 2024

Form: 6-K
On May 14, 2024, Biophytis S.A. issued a press release announcing the design of its phase 2 OBA clinical study in obesity.
Ouvrir le document

April 29, 2024

Form: 6-K
On April 29, 2024, Biophytis S.A. issued a press release announcing the implementation of a dedicated strategy for partner search in obesity.
Ouvrir le document

April 25, 2024

Form: 6-K
On April 24, 2024, Biophytis S.A. issued a press release announcing the transfer of ADSs to OTC market.
Ouvrir le document

April 18, 2024

Form: 6-K
On April 18, 2024, Biophytis S.A. issued a press release announcing the formation of a new Scientific Advisory Board for its phase 2 OBA clinical study in obesity.
Ouvrir le document

April 15, 2024

Form: 6-K On April 15, 2024, Biophytis S.A. issued a press release announcing the filing of a patent application and that the company strengthens its intellectual property
in obesity.
Ouvrir le document

April 9, 2024

Form: 6-K
On April 8, 2024, Biophytis S.A. issued a press release announcing its 2023 financial results and provides an update on its business activities.
Ouvrir le document

April 9, 2024

Form: 6-K
On April 8, 2024, Biophytis S.A. issued a press release announcing that it launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone).
Ouvrir le document

April 8, 2024

Form: 20-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the fiscal year ended December 31, 2023.
Ouvrir le document

April 5, 2024

Form: 6-K
On April 4, Biophytis S.A. issued a press release announcing the results of the Combined General Meeting on April 2, 2024.
Ouvrir le document

March 22, 2024

Form: 6-K
On March 22, 2024, Biophytis S.A. issued a press release announcing that the company presented its phase 3 protocol in the treatment of sarcopenia at the International Conference on Frailty and Sarcopenia Research (ICFSR) held from March 20 to 22, 2024 in Albuquerque, NM, USA.
Ouvrir le document

March 18, 2024

Form: 6-K
On March 18, 2024, Biophytis S.A. issued a press release announcing that a Combined General Meeting will be held on April 2, 2024.
Ouvrir le document

March 15, 2024

Form: 6-K
On March 15, 2024, Biophytis S.A. issued a press release announcing the implementation of a reserve stock split of its ordinary shares.
Ouvrir le document

March 12, 2024

Form: 6-K
On March 12, 2024, Biophytis S.A. issued a press release announcing its participation in several events in Europe and the United States over the coming months.
Ouvrir le document

March 8, 2024

Form: 6-K On March 8, 2024, Biophytis S.A. issued a press release announcing that the company presented the results of its recent clinical trials with Ruvembri™ at the
Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, held from 3 to 6 March 2024 in Orlando, USA.
Ouvrir le document

January 5, 2024

Form: 6-K
On January 4, 2024, Biophytis S.A. issued a press release announcing the publication of the results of its COV A phase 2-3 study in, eClinicalMedicine, part of The Lancet.
Ouvrir le document

January 5, 2024

Form: 6-K
On December 29, 2023, Biophytis S.A. issued a press release announcing the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract.
Ouvrir le document

December 11, 2023

Form: 6-K
On December 11, 2023, Biophytis S.A. issued a press release announcing its participation in several conferences in Europe and the US during the first quarter of 2024.
Ouvrir le document

December 05, 2023

Form: 6-K
On December 4, 2023, Biophytis S.A. issued a press release announcing that Biophytis and the University of Liège explore the potential of Sarconeos (Ruvembri) in the treatment of viral respiratory failure.
Ouvrir le document

November 21, 2023

Form: 6-K
On November 17, 2023, Biophytis S.A. issued a press release announcing receipt of Nasdaq Notice.
Ouvrir le document

November 20, 2023

Form: 6-K
On November 20, 2023, Biophytis S.A. issued a press release announcing the success of its capital increase with preferential subscription rights for approximately € 1.96 million.
Ouvrir le document

November 7, 2023

Form: 6-K
On November 6, 2023, Biophytis S.A. issued a press release announcing that the company is attending the BIO-Europe conference held in Munich, Germany, November 6th to 8th 2023.
Ouvrir le document

October 30, 2023

Form: 6-K
On October 30, 2023, Biophytis S.A. issued a press release announcing that Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (Ruvembri) in Brazil.
Ouvrir le document

October 26, 2023

Form: 6-K
On October 27, 2023, Biophytis S.A. issued a press release, a copy of which is attached as Exhibit 99.1 to this Form 6-K.
Ouvrir le document

October 23, 2023

Form: 6-K
On October 23, 2023, Biophytis S.A. issued a press release announcing the launch of a rights issue with maintenance of shareholders’ preferential subscription rights to continue the execution of its strategic roadmap.
Ouvrir le document

September 27, 2023

Form: 6-K
On September 27, 2023, Biophytis S.A. (the “Company”) issued its Interim Financial Report for the first half of fiscal year 2023.
Ouvrir le document

September 25, 2023

Form: 6-K
On September 25, 2023, Biophytis S.A. issued a press release announcing that Biophytis and Skyepharma have signed a Partnership Agreement for the Production of Sarconeos (Ruvembri).
Ouvrir le document

September 19, 2023

Form: 6-K
On September 19, 2023, Biophytis S.A. issued a press release providing an update on its early access programs for Sarconeos (Ruvembri) in the treatment of severe forms of COVID-19.
Ouvrir le document

September 14, 2023

Form: 6-K
On September 14, 2023, Biophytis S.A. issued a press release announcing that Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer.
Ouvrir le document

September 11, 2023

Form: 6-K
On September 11, 2023, Biophytis S.A. issued a press release announcing that it has obtained FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia.
Ouvrir le document

September 4, 2023

Form: 6-K
On September 4, 2023, Biophytis S.A. issued a press release announcing its participation at the H. C. Wainwright 25th Global Investment Conference in New York.
Ouvrir le document

August 16, 2023

Form: 6-K
On August 16, 2023, Biophytis S.A. issued a press release announcing next regulatory steps in Europe and the United States for its COVA project.
Ouvrir le document

August 8, 2023

Form: 6-K
On August 8, 2023, Biophytis S.A. issued a press release announcing that it received a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe.
Ouvrir le document

July 21, 2023

Form: 6-K
On July 18, 2023, Biophytis S.A. entered into an investor subscription agreement with an institutional investor, pursuant to which the Company agreed to sell and issue to the investor 505,000 units of ordinary shares with ordinary warrants attached.
Ouvrir le document

July 20, 2023

Form: 6-K
On July 20, 2023, Biophytis S.A. issued a press release announcing it has requested a pre-submission meeting with the FDA for an Emergency Use Authorization of Sarconeos (Ruvembri) for the treatment for COVID 19.
Ouvrir le document

July 19, 2023

Form: 6-K
On July 19, 2023, Biophytis S.A. issued a press release announcing $3.8 Million Registered Direct Offering.
Ouvrir le document

July 18, 2023

Form: 6-K
On July 18, 2023, Biophytis S.A. issued a press release announcing that Biophytis and Seqens have signed a partnership to produce Sarconeos (Ruvembri) active compound.
Ouvrir le document

July 10, 2023

Form: 6-K
On July 10, 2023, Biophytis S.A. issued a press release announcing it has filed with the FDA for authorization to initiate SARA-31 phase 3 study in sarcopenia.
Ouvrir le document

July 3, 2023

Form: F-3
Registration Statement
Ouvrir le document

July 3, 2023

Form: 20-F/A
Amendment No.1 to Form 20-F/A filed on April 19, 2023.
Ouvrir le document

June 19, 2023

Form: 6-K
On June 19, 2023, Biophytis S.A. issued a press release announcing that it reports clinical results for Sarconeos (Ruvembri) in sarcopenia treatment at the 16th SCWD International Congress.
Ouvrir le document

June 16, 2023

Form: 6-K
On June 16, 2023, Biophytis S.A. issued a press release announcing the approval by a large majority of all resolutions presented by the company and falling within the remit of the Annual General Meeting.
Ouvrir le document

June 5, 2023

Form: 6-K
On June 5, 2023, Biophytis S.A. issued a press release announcing its participation at the BIO International Convention in Boston from the 5th to the 8th of June.
Ouvrir le document

May 26, 2023

Form: 6-K
On May 26, 2023, Biophytis S.A. issued a press release announcing that the company has filed with the French National Authority for Health (HAS) an application for Early Access Authorisation (EAA) for Sarconeos (Ruvembri).
Ouvrir le document

May 25, 2023

Form: 6-K
On May 25, 2023, Biophytis S.A. issued a press release announcing its presentation of positive results of Phase 2-3 COVA study at the American Thoracic Society International Conference.
Ouvrir le document

May 15, 2023

Form: 6-K
On May 15, 2023, Biophytis S.A. issued a press release announcing that the company has filed with the EMA for authorization to initiate SARA-31 phase 3 study in sarcopenia.
Ouvrir le document

May 11, 2023

Form: 6-K
On May 11, 2023 Biophytis S.A. issued a press release announcing a successful capital increase with €2.3 million raised.
Ouvrir le document

May 9, 2023

Form: 6-K
On May 9, 2023, Biophytis S.A. issued a press release announcing it has requested a pre-submission meeting with the EMA for the Marketing Authorisation of Sarconeos (Ruvembri) for the treatment of COVID-19
Ouvrir le document

May 2, 2023

Form: 6-K
On May 2, 2023, On May 2, 2023, Biophytis S.A. issued a press release announcing the strengthening of its management team.
Ouvrir le document

April 28, 2023

Form: 6-K
On April 28, 2023, Biophytis S.A. issued a press release announcing receipt of Nasdaq Notice.
Ouvrir le document

April 19, 2023

Form: 6-K
On April 19, 2023, Biophytis S.A. issued a press release announcing that Biophytis regains compliance with NASDAQ minimum bid price requirement.
Ouvrir le document

April 19, 2023

Form: 20-F/A
 Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2022
Ouvrir le document

April 18, 2023

Form: 6-K
 On April 18, 2023, Biophytis S.A. issued a press release announcing 2022 Financial Results and 2023 Perspectives. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.
Ouvrir le document

March 31, 2023

Form: 6-K
 On March 31, 2023, Biophytis S.A. issued a press release informing that the Extraordinary General Meeting of the company held on March 30, 2023 could not be held on first notice, as the required quorum was not reached. The quorum necessary for holding an extraordinary General Meeting on first call IS 25%.
Ouvrir le document

March 27, 2023

Form: 6-K
On March 27, 2023, Biophytis S.A. issued a press release announcing the presentation of Sarconeos (Ruvembri) as a possible treatment candidate for long COVID after hospitalization during the 13th annual International Conference on Frailty and Sarcopenia Research (ICFSR).
Ouvrir le document

March 20, 2023

Form: 6-K
On March 20, 2023, Biophytis S.A. issued a press release announcing the presentation of Sarconeos’ (Ruvembri) Development as a Drug Candidate in Rare Neuromuscular Diseases at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
Ouvrir le document

March 17, 2023

Form: 6-K
On March 17, 2023, Biophytis S.A. issued a press release announcing ratio change under its American Depository Receipt (“ADR”) program.
Ouvrir le document

March 09, 2023

Form: 6-K
On March 9, 2023, Biophytis S.A. issued a press release presenting positive results of Phase 2-3 COVA Study at ERS 2023 21st Lung Science Conference.
Ouvrir le document

March 02, 2023

Form: 6-K
On March 2nd, 2023, Biophytis S.A. issued a press release announcing the signature of a master service agreement with Intsel Chimos, a pharmaceutical company that will operate Sarconeos (Ruvembri) in France for the treatment of severe forms of COVID-19.
Ouvrir le document

February 23, 2023

Form: 6-K
On February 23, 2023, Biophytis S.A. issued a press release announcing it is convening an Extraordinary and Ordinary Shareholder’s Meeting for March 30, 2023.
Ouvrir le document

February 02, 2023

Form: 6-K
On February 2, 2023, Biophytis S.A. issued a press release announcing positive final results of the phase 2-3 COVA study with Sarconeos (B10101) in severe COVID-19.
Ouvrir le document

January 31, 2023

Form: 6-K
On January 31, 2023, Biophytis S.A. issued a press release announcing the publication of its interim financial report for the first half of 2022 and its adjusted financial results as of 31 December 2021.
Ouvrir le document

January 31, 2023

Form: 20-F/A
Annual report pursuant to section 13 or 15(d) of the securities exchange act of 1934.
Ouvrir le document

January 30, 2023

Form: 6-K
On January 30, 2023, Biophytis S.A. (the “Company” issued its Interim Financial Report for the first half of fiscal year 2022.
Ouvrir le document

January 19, 2023

Form: 6-K
On January 19, 2023, Biophytis S.A. issued a press release announcing that the Paris Court of appeal confirms the judgement of the Paris Commercial Court of 16th March 2021.
Ouvrir le document

January 06, 2023

Form: 6-K
On January 5, 2023, Biophytis S.A. issued a press release announcing its participation in two major investor conferences in January, in the United States and in France : the JP Morgan Healthcare Conference and the Invest Securities Biomed Event.
Ouvrir le document

November 30, 2022

Form: 6-K
On November 30, 2022, Biophytis S.A. issued a press release announcing the organization of a webcast with key opinion leaders (KOL) on the phase 2-3 COVA study results of Sarconeos (Ruvembri) in the treatment of pneumonia in COVID-19 patients at risk of respiratory failure.
Ouvrir le document

October 31, 2022

Form: 6-K
On October 31, 2022, Biophytis S.A. issued a press release announcing the publication of its key financial figures as at 30 June 2022 and a restatement of the financial statements published as of December 31st, 2021 and providing and update on the operational milestones.
Ouvrir le document

October 26, 2022

Form: 6-K
On October 26, 2022, Biophytis S.A. issued a press release announcing receipt of Nasdaq Notice.
Ouvrir le document

September 15, 2022

Form: 6-K
On September 15, 2022, Biophytis S.A. issued a press release announcing that the company will participate in HCW 24th Annual Global Investment conference.
Ouvrir le document

September 13, 2022

Form: 6-K
On September 13, 2022, Biophytis S.A. issued a press release announcing that the Paris Court of appeal rules in favour of Biophytis in the case against Negma Group Ltd.
Ouvrir le document

September 07, 2022

Form: 6-K
On September 7, 2022, Biophytis S.A. issued a press release announcing very promising top line results of its phase 2-3 COVA clinical study in COVID-19 related to respiratory failure.
Ouvrir le document

July 04, 2022

Form: 6-K
On July 4, 2022, Biophytis S.A. issued a press release providing an update on the development of Sarconeos (Ruvembri) in Covid-19 at the 4th Annual Longevity Therapeutics Summit.
Ouvrir le document

June 30, 2022

Form: 6-K
On June 30, 2022, Biophytis S.A. issued a press release announcing the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for €4 million.
Ouvrir le document

June 27, 2022

Form: 6-K
On June 27, 2022, Biophytis S.A. issued a press release presenting the development of Sarconeos (Ruvembri) in Phase 3 for the treatment of Sarcopenia at the 15th SCWD International Congress.
Ouvrir le document

June 22, 2022

Form: 6-K
On June 22, 2022, Biophytis S.A. issued a press release announcing the results of the Combined General Meeting held on June 21, 2022.
Ouvrir le document

June 16, 2022

Form: 6-K
On June 16, 2022, Biophytis S.A. issued a press release presenting preclinical efficacy data for Sarconeos (Ruvembri) in Spinal Muscular Atrophy (SMA), a rare neuromuscular disease.
Ouvrir le document

June 3, 2022

Form: 6-K
On June 3, 2022, Biophytis S.A. issued a press release announcing the Convening of Another Combined General Meeting at a Later Date.
Ouvrir le document

May 12, 2022

Form: 6-K
On May 12, 2022, Biophytis S.A. issued a press release announcing its participation at the Bio International Convention in San Diego from the 13th to the 16th of June.
Ouvrir le document

April 21, 2022

Form: 20-F Annual Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934
For The Fiscal Year Ended December 31, 2021
Ouvrir le document

April 19, 2022

Form: 6-K
On April 19, 2022, Biophytis S.A. issued a press release announcing that the company will present Sarconeos (Ruvembri) Development Program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston, April 20-22, 2022
Ouvrir le document

April 7, 2022

Form: 6-K
On April 7, 2022, Biophytis S.A. issued a press release announcing 2021 Operational and Financial Results and Gives Updates on 2022 Perspectives
Ouvrir le document

April 5, 2022

Form: 6-K
On April 5, 2022, Biophytis S.A. issued a press release announcing the appointment of Philippe Rousseau as Chief Financial Officer
Ouvrir le document

March 16, 2022

Form: 6-K
On March 16, 2022, Biophytis S.A. issued a press release announcing that the company will participate in a key conference on mobility for the elderly
Ouvrir le document

February 4, 2022

Form: 6-K
On February 3, 2022, Biophytis S.A. issued a press release announcing that the company received approval from ANVISA (Brazil) to give access to Sarconeos (Ruvembri) to hospitalized COVID-19 patients through an Expanded Access Program
Ouvrir le document

December 23, 2021

Form: 6-K
On December 22, 2021, Biophytis S.A. issued a press release announcing the drawing of the last tranche of ORNANE under the 2020 Atlas contract for 3 million.
Ouvrir le document

December 17, 2021

Form: 6-K
On December 16, 2021, Biophytis S.A. issued a press release announcing that the company is to meet with FDA to advance Sarconeos (Ruvembri) development in Sarcopenia from Phase 2 to Phase 3
Ouvrir le document

November 23, 2021

Form: 6-K
On November 22, 2021, Biophytis S.A. issued a press release announcing the obtaining of a new 10M€ loan structure with Kreos Capital
Ouvrir le document

November 15, 2021

Form: 6-K
On November 15, 2021, Biophytis S.A. issued a press release announcing US centers to restart recruitment for the COVA phase 2-3 study with Sarconeos (Ruvembri) in COVID 19
Ouvrir le document

October 29, 2021

Form: 6-K
On October 29, 2021, Biophytis S.A. issued a press release reporting Restated Financial Statements for Previous Periods and as of June 30, 2021.
Ouvrir le document

October 29, 2021

Form: 20-F Annual Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934.
For The Fiscal Year Ended December 31, 2020
Ouvrir le document

October 29, 2021

Form: 6-K
On October 28, 2021, Biophytis S.A. (the “Company” issued its Interim Financial Report for the first half of fiscal year 2021.
Ouvrir le document

October 06, 2021

Form: 6-K
Biophytis S.A. issued a press release announcing it will host a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (Ruvembri) for the treatment of COVID-19 and Sarcopenia
Ouvrir le document

October 05, 2021

Form: 6-K
On October 4, 2021, Biophytis S.A. issued a press release announcing the drawing of 2 new tranches of ORNANE under the 2020 Atlas contract for € 6 million
Ouvrir le document

October 04, 2021

Form: 6-K
 Biophytis announces promising full results from the SARA-INT Phase 2b trial of Sarconeos (Ruvembri) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR). September 29 – October 2, 2021
Ouvrir le document

September 30, 2021

Form: 6-K
Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos (Ruvembri) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29–October 2, 2021
Ouvrir le document

September 17, 2021

Form: 6-K
Biophytis reports H1 2021 financial results and provides business update
Ouvrir le document

September 15, 2021

Form: 6-K
Biophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (Ruvembri) in COVID-19
Ouvrir le document

June 30, 2021

Form: 6-K
Biophytis announces that the results of SARA-INT Phase 2 Trial with Sarconeos (Ruvembri) in Sarcopenia will be released by August 2021
Ouvrir le document

June 30, 2021

Form: 6-K
Biophytis announces that it will secure the manufacturing of Sarconeos (Ruvembri) for COVID-19 with a global CDMO and the next milestones for the COVA Phase 2-3 study
Ouvrir le document

-June 18, 2021

Form: 6-K
Biophytis announces new convertible bonds financing upt to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
Ouvrir le document

May 12, 2021

Form: 6-K
Biophytis Completed the Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (Ruvembri) in COVID-19 allowing the 2nd Interim Analysis
Ouvrir le document

May 11, 2021

Form: 6-K
Results of the Combined General Meeting on May 10, 2021
Ouvrir le document

April 30, 2021

Form: 6-K
Biophytis Second Combined General Meeting to take place on May 10, 2021 without the physical presence of its shareholers
Ouvrir le document

April 29, 2021

Form: 6-K
Biophytis Receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD
Ouvrir le document

April 27, 2021

Form: 6-K
Convening of another Combined General Meeting at a later date
Ouvrir le document

April 26, 2021

Form: 6-K
Biophytis gives operational perspectives on its Sarconeos (Ruvembri) ahead of its upcoming AGM on April 26, 2021
Ouvrir le document

March 22, 2021

Form: 6-K
Biophytis gives update on its Phase 2-3 COVA study on COVID-19
Ouvrir le document

March 19, 2021

Form: 6-K
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd
Ouvrir le document

March 12, 2021

Form: 6-K
Annual General Meeting will take place on April 26, 2021
Ouvrir le document

March 11, 2021

Form: 20-F
Annual Report for the Fiscal Year Ended Dec 31, 2020
Ouvrir le document

Feb 26, 2021

Form: 6-K
Biophytis Reports 2020 Full Year Results
Ouvrir le document

Feb 17, 2021

Form: 6-K
Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial
Ouvrir le document

Feb 16, 2021

Form: 6-K
Report of Foreign Private Issuer
Ouvrir le document

Feb 9, 2021

Form: 6-K
Final Prospectus
Ouvrir le document

Feb 9, 2021

Form: F-1
Amendment No 3
Ouvrir le document

Feb 8, 2021

Form: FWP
Free Writing Prospectus
Ouvrir le document

Feb 4, 2021

Form: F-8A
For Registration of Certain Classes of Securities Pursuant to Section 12(b) or (g)
Ouvrir le document

Feb 4, 2021

Form: F-1
Amendment No 2
Ouvrir le document

Feb 2, 2021

Form: FWP
Free Writing Prospectus
Ouvrir le document

Feb 2, 2021

Form: F-1
Amendment No 1
Ouvrir le document

Jan 19, 2021

Form: F-1
Form F-1
Ouvrir le document

Dec 23, 2020

Form: F-1
Draft Registration Statement
Ouvrir le document

Nov 20, 2020

Form: F-1
Draft Registration Statement
Ouvrir le document